Organization (Academic)
UNIVERSITY OF PRETORIA
ClinicalTrials.gov lists UNIVERSITY OF PRETORIA as lead sponsor of 17 trials. It has 7 active development programs and 5 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers UNIVERSITY OF PRETORIA: 17 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (27)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 4 |
| Hearing Loss | 3 |
| Diabetes Mellitus, Type 2 | 2 |
| HIV Infections | 2 |
| Uterine Cervical Neoplasms | 2 |
Showing 5 of 27 disease areas.
Trials by start year as sponsor or collaborator (14)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 3 |
| 2019 | 1 |
| 2018 | 3 |
| 2017 | 3 |
| 2016 | 2 |
Showing 10 of 14 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (7)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Hepatitis B Vaccine | Papillomavirus Infections | Phase 3 | 1 |
| Quadrivalent HPV Vaccine | Warts | Phase 3 | 1 |
| Quadrivalent HPV Vaccine | Papillomavirus Infections | Phase 3 | 1 |
| Quadrivalent HPV Vaccine | Condylomata Acuminata | Phase 3 | 1 |
| Hepatitis B Vaccine | Condylomata Acuminata | Phase 3 | 1 |
Showing 5 of 7 active programs.
Approved assets (5)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Metronidazole | 1 |
| Adenosine | 1 |
| Hepatitis B Vaccine | 1 |
| Ginkgo Biloba | 1 |
| Oxytocin | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 40% hit target (n=5) | 60% on time (n=5) |
Journals published in (39)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| International journal of audiology | 7 |
| PloS one | 3 |
| American journal of audiology | 2 |
| American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists | 2 |
| Audiology research | 2 |
Showing 5 of 39 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 37 | 10 | 2025-07-15 |
Financing and grant events (8)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-08-27 | NIH grant | 132,331 | Reporter |
| 2024-08-23 | NIH grant | 70,827 | Reporter |
| 2024-03-19 | NIH grant | 133,719 | Reporter |
| 2023-04-17 | NIH grant | 137,000 | Reporter |
| 2023-02-10 | NIH grant | 139,854 | Reporter |
Showing 5 of 8 events.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 5 | 2009-09-30 |
Organization relationships (11)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University of Cape Town | Co sponsors trial with | 2 |
| University of Bern | Co sponsors trial with | 1 |
| Louisiana State University System | Co sponsors trial with | 1 |
| University of Southern California | Co sponsors trial with | 1 |
| Leona M. and Harry B. Helmsley Charitable Trust | Co sponsors trial with | 1 |
Showing 5 of 11 relationships.
Latest dated events (73)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-08-27 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-07-15 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-05-21 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 73 events.
Biomarker capability evidence (7)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| CYP11B1 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| PTBP1 | Trial sponsor | Named in trial exclusion criteria |
| PTBP2 | Trial sponsor | Named in trial exclusion criteria |
| CD4 | Trial sponsor | Mentioned in trial text |
Showing 5 of 7 evidence rows.
Biomarkers this organization publishes on (159)
Shown in this order: most publications first.
Showing 5 of 159 biomarkers.
On Scientist.com
UNIVERSITY OF PRETORIA is linked to 2 research suppliers in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.
Work with University of Pretoria on Scientist.com
For prices, more details, or to contact University of Pretoria, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.